Labcorp Plasma Complete
Laboratory Corporation of America has launched Labcorp Plasma Complete, a circulating tumor DNA-based genomic profiling test for patients with solid tumors. Oncologists can use the liquid biopsy test to perform a genomic profile of patients from a blood draw to inform personalized treatment plans. The test detects genomic alterations in ctDNA in 521 genes, including single-nucleotide variants and insertions and deletions, as well as amplifications in 12 genes, translocations associated with 12 genes, and microsatellite instability-high status, Labcorp said. The assay covers established and emerging biomarkers linked to therapies approved by the US Food and Drug Administration, guideline-driven therapies, and clinical trial eligibility. It offers a reportable range with a variant allele frequency as low as 0.10 percent and a specificity greater than 99.99 percent, Labcorp said.
Bruker DeutEx, OmniScape 2025, ProteoScape V.2025c, and TwinScape
Bruker has launched several software packages for mass spectrometry.
Its DeutEx software is intended for the analysis of hydrogen-deuterium exchange mass spectrometry and supports the company's TimsTOF, MRMS, and MALDI-TOF systems.
Its OmniScape 2025 software offers improved performance for de novo sequencing, detection of truncated variants, and reliable sequence annotation as well as integration of sequence maps derived from different MSn levels.
ProteoScape V.2025c provides updated versions of Spectronaut and GlycoScape software.
TwinScape is a cloud-based AI-enabled quality monitoring software package.
Claret Bioscience REALLY hg-rNONE
Claret Bioscience has launched its REALLY hg-rNONE kits for depletion and whole-blood RNA-seq. This library workflow for Illumina sequencing adds to the company's REALLY line of RNA-seq products. REALLY is a single-stranded library prep method that circumvents second-strand synthesis and end-polishing, generating directional libraries without superfluous steps. With hg-rNONE probes, both ribosomal RNA reads and hemoglobin transcripts are simultaneously depleted following adapter ligation, the company said. The kit contains reagents for gDNA removal, first-strand synthesis adapter ligation, depletion, and indexing PCR, as well as magnetic beads for purification.
PGxAI Vega
PGxAI, a Palo Alto, California-based provider of AI-powered pharmacogenetics solutions, has launched Vega, its latest AI model designed to help physicians and health systems tailor drug therapy based on individual genetic profiles. Vega covers more than 1,200 drugs and 350 genes, which the company claims is 70 times the scope of traditional pharmacogenetic panels, made possible by the company's foundational GenAI model. The new platform also builds on the company's previous model, Sirius, which focused on risk classification by identifying patients prone to adverse drug reactions. The new model also interprets clinical guidelines and instantly generates treatment recommendations.
For more recently launched products and services, please visit the New Products page on our website.